For emerging biotech companies operating with lean internal teams, outsourcing critical regulatory documents can be essential to maintaining momentum toward first‑in‑human studies.
Overview
Support needed for Global Clinical Pathways
A US‑based biotech had in‑licensed an early‑stage immunology and dermatology asset originating from China and was approaching entry into clinical trials. Their development strategy involved initiating a Phase 1 study in Australia, followed by engagement with the US FDA for later‑phase clinical development.
With no internal medical writing function, they sought an experienced partner who could deliver under pressure and integrate seamlessly with a consultant‑led regulatory team and Subject Matter Experts (SME).
With source data originating from China and a compressed timeline spanning the holiday period, Morula Health was engaged to review and refine a translated Investigator’s Brochure to ensure alignment with Australian (TGA) and US (FDA) regulatory expectations and was suitable for submission.
The challenge
The Investigator’s Brochure was a critical path document for the client’s clinical strategy. The project presented several challenges:
- Source materials originated from multiple contributors, with all underlying data initially generated in Chinese
- The translated IB required substantial review and editing to meet FDA and TGA expectations
- The client was working toward fixed regulatory milestones, with the IB needed over the Christmas and New Year period
- Internal stakeholders and consultants were operating in parallel, requiring flexibility and close coordination
The biotech needed a team that could move quickly, apply regulatory judgment, and maintain document quality despite evolving inputs and limited turnaround time.
The Solution
Morula Health assembled a focused project team, led by an experienced Investigator’s Brochure medical writer with deep familiarity with global regulatory requirements.
Working closely with the client’s regulatory lead and SMEs, we:
✔ Conducted an expedited kick-off and scoped the review approach around the client’s clinical and regulatory strategy.
✔ Reviewed and edited the translated IB to ensure clarity, internal consistency, and alignment with FDA and TGA regulatory expectations
✔ Adapted working practices to accommodate real‑time document updates as translated source materials became available
Despite the compressed timeline, Morula Health delivered a structured, regulator‑ready Investigator’s Brochure that supported both near‑term submission to Australian regulators and longer‑term FDA engagement.
The Outcome
- The Investigator’s Brochure was finalized on time and in line with the client’s regulatory milestones
- The project was completed under budget despite significant complexity and time pressure
- The client expressed high confidence in the quality and readiness of the final document
- Morula Health was subsequently engaged to support preparation of the pre-IND briefing package
By combining regulatory insight, flexible delivery, and experienced IB authorship, Morula Health helped the client de‑risk a critical transition point in their early clinical development program.
Your Partner for Time‑Critical Regulatory Documents
Whether refining an Investigator’s Brochure, preparing for early‑phase clinical trials, or supporting global regulatory strategies, Morula Health delivers experienced medical writing support when it matters most.
Key Takeaway
for Biotechs
The biotech needed a team that could move quickly, apply regulatory judgment, and maintain document quality despite evolving inputs and limited turnaround time.
Morula Health partnered closely with the biotech’s regulatory team and SME to review and refine an Investigator’s Brochure originally developed by a Chinese CRO, ensuring the document was submission‐ready for Australia (TGA) and supportive of subsequent US (FDA) regulatory discussions.
Get in touch to discuss how we can help.
WHY BIOTECHS CHOOSE MORULA HEALTH
✔ Deep, designation‑specific regulatory expertise
✔ Strategic leadership that reduces risk and internal burden
✔ Efficient, high‑quality delivery with built‑in quality control
Read our full guide here:
How to write and update an IB for clinical trials aligned with ICH E6(R3)
Industry Insights
The Value of an Integrated Medical Writing Partner
As development programs progress, the volume and complexity of scientific documentation increase significantly. From investigator’s brochures (IBs), clinical study protocols, and briefing packages to…
Find out more
Your IND Application Is Only as Strong as the Documents Behind It
A well-prepared IND is a signal of scientific credibility to future partners, investors, and licensing counterparts.
Find out more
What Should You Look For In A Medical Writing Service Provider?
An increasing number of research teams, including those in the biotech industry, are choosing to outsource their medical writing needs to external service providers.
Find out more